Its new use is based on an analysis of the phase 3 IMPACT study, which showed Trelegy was better than GSK’s already approved combinations Relvar/Breo Ellipta and Anoro Ellipta. Trelegy is also ...
It contains an inhaled corticosteroid, a long-acting muscarinic antagonist and a long-acting beta2-adrenergic agonist, delivered once daily in GSK’s Ellipta dry powder inhaler, which is used ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback